⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
Apollo Therapeutics Appoints Timothy P. Walbert as Chairman of the Board
globenewswire.com
AMGN
ABBV
BMRN
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
prnewswire.com
ABBV
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
prnewswire.com
ABBV
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight
globenewswire.com
AMRX
ARX
GSK
AZN
SNY
NVS
MRK
REGN
JNJ
PFE
BMY
LLY
VRTX
AMGN
ABBV
GILD
BIIB
CSL
AQST
RAPT
ALGT
Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight
prnewswire.com
ABBV
El Meijer LPGA Classic for Simply Give 2026 regresa con las experiencias familiares favoritas de los fanáticos USA - español USA - English
prnewswire.com
V
MSFT
GOOG
AMZN
M
TGT
WMT
KR
COST
PG
JNJ
KO
PEP
MCD
SBUX
DIS
CMCSA
NFLX
AMAT
NVDA
INTC
AMD
QCOM
MU
TXN
ADI
NXPI
MRVL
SNPS
CDNS
ASML
LRCX
KLAC
AMGN
GILD
BMY
PFE
MRK
ABBV
LLY
JPM
BAC
WFC
C
GS
MS
AXP
IBM
ORCL
CRM
CSCO
ACN
ADP
NOW
ADBE
EA
TTWO
CRSP
REGN
VRTX
BIIB
ALGN
EXPE
BKNG
MAR
HPE
DELL
HPQ
AVGO
ADSK
PAYX
FISV
PYPL
MELI
EBAY
BABA
JD
PDD
NIO
XPEV
LI
TSLA
RIVN
LCID
GM
F
STLA
TM
HMC
VWAGY
BBD
AAPL
META
SNAP
PINS
Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsight
prnewswire.com
AEON
ABBV
SUPN
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
prnewswire.com
ABBV
DigiCert Research Reveals Major Certificate Visibility Blind Spot for Enterprises
globenewswire.com
MSFT
GOOG
AMZN
IBM
ORCL
CSCO
DELL
HPQ
INTC
QCOM
NVDA
AMD
AVGO
MU
AMAT
LRCX
KLAC
ADI
TXN
NXPI
MRVL
SNPS
CDNS
ADSK
CRM
ACN
INFY
SAP
PANW
CRWD
OKTA
FTNT
DDOG
NOW
MCHP
ON
LULU
BBY
COST
HD
LOW
TJX
MDT
AMGN
GILD
BMY
PFE
MRK
JNJ
ABBV
LLY
BIIB
REGN
VRTX
AZN
SNOW
SMCI
PLTR
AI
GOOGL
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
prnewswire.com
ABBV